Bilgiustam

Symptom Management in Dementia Palliative Care


Physical symptoms commonly experienced by people with advanced dementia include pain, difficulties with hydration and nutrition, dyspnoea, and infection. Non-pharmacological approaches are often primary care and there are medications used as needed to meet maintenance goals. For patients in the terminal stage of dementia, parenteral administration of drugs is often, but not always necessary, due to swallowing problems.

pain

Pain is common among people with advanced dementia, such as from concomitant illnesses, current or previous injuries, poor oral health, and bed pressure injuries. Problems in expressing or communicating the level of pain can lead to behavioral or psychological symptoms of dementia (BPSD) and thus improper prescription of antipsychotics in place of adequate pain relief. It can be detected using a pain tool such as the dementia-specific Abbey pain scale, as well as clinical evaluation to identify pain in people with dementia.
In addition, constipation can occur in recyclable pain such as improper wearing of tools and supports that help with hearing or movements, immobility, infection, and previous chronic pain history. Therefore, these should be taken into consideration. Once all this has been addressed, the patient’s pain should be re-evaluated. Important recommendations about pain management in dementia can be listed as follows:

Non-Pharmacological Interventions

Body positioning
Providing a comfortable and supportive seating or bed
• Massage
Environmental changes, such as adjusting the temperature or lighting, playing music
• Improving sleep
• Practicing spiritual or belief activities
Social and cultural participation
Symptom Management in Dementia Palliative CareIf analgesia is indicated, a step-by-step approach following the general principles of the WHO analgesic ladder is recommended, starting with regular paracetamol. There is limited evidence to guide NSAID use in people with dementia, but they can be carefully considered in combination with paracetamol before stepping into an opioid.
• When accelerating the treatment, expert opinion is that the WHO analgesic ladder (eg codeine or tramadol) 2. It is preferable to start with a low dose of strong opioid (morphine) in terms of efficacy and tolerability.
• There is limited data on opioid use in people with dementia, and there is uncertainty about its effectiveness and sensitivity to adverse effects in this group. Considering potential drug interactions, adverse effects should be monitored by administering low-dose and gradually increasing medication.
• Consideration should be given to alternative formulations (eg liquid) and administration routes (eg subcutaneous or transdermal) for patients with swallowing difficulties.

Nutrition and Hydration

Advanced dementia is associated with a reduced desire to eat, forgetting how to eat or what food is, and a loss of ability to chew and swallow, which can result in reduced calorie intake and weight loss. Strategies that can help improve oral intake include:
• Ensuring that the patient has no underlying oral health problems and has good oral hygiene, such as prosthetic care
• Providing quality, attractively presented and catering meal options at multiple sensory levels to maximize cooking tips
• Providing foods appropriate to the patient’s cognitive level and their ability to swallow, such as pre-cut, softer or mashed foods, more frequent feeding with smaller portion sizes, feeding with finger-holding foods as the ability to use cutlery is lost
• Allowing more time for the person to eat in an environment that minimizes distraction.
• A swallowing assessment is often required to manually feed the person and to check safety; consulting a speech / language therapist if needed
• Oral nutritional supplements (eg Ensure or Fortisip) may be considered for patients who are malnourished and cannot maintain body weight through food intake alone. These should be given between meals, not instead of meals.
• Consider a care plan that may include consulting a dietitian for nutritional assessment and recommendations for strategies such as food fortification (e.g. with iron if deficient), meal timing / frequency, and oral nutritional support.
Symptom Management in Dementia Palliative CareIf patients with advanced dementia are unable to swallow tablets required for symptomatic treatment, alternative formulations (eg liquid) and routes of administration (eg subcutaneous or transdermal) should be considered. If necessary, preventive treatments such as statins, anti-hypertensives, aspirin, bisphosphonates are likely to be discontinued at this stage.
In addition, the role of artificial hydration and nutrition is limited for people with advanced dementia. Persistent loss of appetite, weight loss, difficulty swallowing or recurrent aspiration in a person with advanced dementia, consensus should be reached with the person’s family or caregiver about maintaining nutrition and hydration. Ideally, the person’s preferences would be discussed and documented in the care plan.
Artificial feeding (enteral feeding tubes or parenteral feeding) is generally not recommended for people with advanced dementia and is generally accepted only if requested by the family and is clinically appropriate.6 Artificial feeding does not increase survival and does not improve pain, infection or bleeding, diarrhea, constipation and reflux, aspiration It is associated with potential damages such as complications from tube placement such as pneumonia and fluid overload. Subcutaneous or intravenous fluids can be used with caution, avoiding fluid overload during an acute illness. Parenteral fluids are generally unsuitable at the end of life; It can be used to relieve dry mouth symptoms instead of swabs or saliva soaked in water.

Dyspnoea

The incidence of dyspnea (shortness of breath) increases as people approach the end of life. Potential causes include aspiration, pneumonia, heart disease, chronic obstructive pulmonary disease, tumors, asthma, pain (e.g. rib or vertebral fracture), neuromuscular insufficiency, ascites, pleural effusion, anemia, sepsis, and anxiety. It may not always be possible to identify a treatable cause.
It can be difficult to assess dyspnoea in people with advanced dementia because these patients are often unable to self-report symptoms. Indicative signs and symptoms include increased heart and respiratory rates, use of accessory muscles, paradoxical breathing pattern (the abdomen moves with inspiration), restlessness, constant grunting, nasal flare, and fearful looking. The Respiratory Distress Observation Scale (RDOS) scores each of these parameters from zero to two points, and the total score from zero (no distress) to 16 (severe distress). Important recommendations for managing dyspnoea:
• If possible, the underlying cause should be determined and relieved,
• Non-pharmacological interventions should be used to provide symptom relief. For example: Using a ventilator or fresh air on the face, breathing techniques and positioning are not routinely recommended as oxygen can cause irritation and distress, but if the patient is anxious and hypoxic, for example, oxygen saturation <90%, an oxygen trial may be appropriate.
Pharmacological interventions are:
• low dose oral morphine; Treatment should be started at a low dose (i.e. 2.5mg) and carefully titrated upwards to be effective.
• Benzodiazepines can be used to reduce anxiety in situations where other methods (ie opioids) have failed, eg oral lorazepam 500 micrograms (half 1 mg tablet) every four to six hours as needed. These are oral diazepam, 2-5 mg given at night if there is persistent anxiety; midazolam 2 mg to 5 mg subcutaneously every four to six hours as needed or intranasal midazolam (not funded) if the oral route is not available. An increased risk of respiratory depression should be considered when prescribing these medications.
Anticholinergic drugs to reduce secretions (eg hyoscine butylbromide (20 mg, subcutaneous [onaylanmamış endikasyon]There is limited evidence of overall efficacy, but these are prescribed by some clinicians to reduce end-of-life secretions. If the patient is distressed due to the amount of secretion, these should be taken into consideration. These drugs can worsen delirium at the end of life.

Symptom Management in Dementia Palliative Care
Infection

Infections, particularly pneumonia and urinary tract infections (UTIs), are common in people with advanced dementia and can often be the cause of death. Important recommendations for managing infection:
• Infection should be considered in patients with unexplained changes in behavior, eg agitation, increased confusion.
• The decision to treat an infection with antibiotics should be guided by the patient’s care plan, family or caregivers and discussions.
Symptomatic treatments for pneumonia include:
Oxygen testing to relieve dyspnoea should only be applied if the patient is hypoxic and symptomatic.
Opioids can be administered to control pain and dyspnoea,
• Anticholinergic drugs can be applied to reduce secretions,
A benzodiazepine or antipsychotic may be administered to reduce anxiety and agitation after trying low-dose morphine.
Symptomatic treatments for UTI include:
Increasing oral fluid intake (if possible)
• Using urine alkalinizing agent (eg Ural bags)
Pain management
Benzodiazepine or antipsychotic to reduce confusion or agitation with the UTI

Sedation

Sedatives may be required intermittently or continuously in people with advanced dementia. Intermittent sedation is typically used to relieve psychomotor agitation. Continuous sedation (also called palliative sedation) is used only to reduce pain at the end of life when other causes have been addressed or when symptomatic treatments are ineffective. Continuous sedation usually uses much higher doses than intermittent sedation and is typically administered by expert palliative care clinicians. Medications for sedation include:
Benzodiazepines, eg midazolam, lorazepam
Soothing antipsychotics, eg levomepromazine
Strong opioids such as morphine, oxycodone (it should only be considered if the patient is allergic or intolerant to morphine)

References:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600060/
https://palliativecare.org.au/wp-content/uploads/dlm_uploads/2018/05/Dementia-Aus-Palliative-Care-Discussion-Paper-36pp-R5.pdf
https://www.researchgate.net/publication/310511178_Palliative_Care_for_the_Person_with_Dementia_Guidance_Document_5_Pain_Assessment_and_Management

Writer: Ozlem Guvenc Agaoglu


Leave a Reply

Your email address will not be published. Required fields are marked *